Sanofi to face further biosimilar Lantus impact in second half
This article was originally published in Scrip
Executive Summary
Sanofi expects further launches of biosimilars versions of its top-selling diabetes product Lantus (insulin glargine) in Europe in the second half of 2015. There have already been launches in three Eastern European countries, executive vice-president of global commercial operation Peter Guenter told an analyst briefing on Sanofi's second-quarter results on July 30.